Gilead Sciences, Inc.
GILDGilead’s future depends on whether its research engine can consistently replace expiring drug patents with new high-margin therapies.
Because in pharmaceuticals, durability is everything, and Gilead sits at the crossroads of cash flow and patent risk.
Business Model
Patented prescription drugs
Gilead develops and sells branded medicines protected by patents, mainly for HIV, cancer, and viral diseases.
Economic Engine
Extremely high margins
With an 86.7 percent gross margin, each successful drug generates significant profit for years.
Long-Term Lens
Pipeline replacement
The key question is whether new therapies can offset patent expirations over the next two decades.
On this page
Company Story
How do Gilead Sciences, Inc.'s business model and economics hold up on a closer read?
Start with the business itself, then go one layer deeper into the model, the economics, and the long-term case.
“A highly profitable drug powerhouse with strong cash flow, but long-term success hinges on continually replacing aging blockbusters with new breakthroughs.”
What does Gilead Sciences, Inc. actually do?
Gilead discovers, develops, and sells prescription medicines for serious diseases.
- Develops antiviral drugs, especially for HIV
- Sells cancer treatments including cell therapies
- Invests heavily in research to create new patented medicines
Why it matters
Patents create temporary monopolies
When a drug is protected by patents, Gilead can price it at a premium and earn high profits for years.
How does Gilead Sciences, Inc. make money?
Gilead makes money by selling branded medicines at high margins while patents protect them from generic competition.
- Hospitals and pharmacies pay for its HIV and oncology drugs
- Gross margin of 86.7 percent shows strong pricing power
- Operating margin of 40.1 percent reflects scale and efficiency
Economic clue
Strong cash conversion
Free cash flow is about 1.11 times net income, meaning reported profits translate into real cash.
Why do long-term investors keep Gilead Sciences, Inc. on the radar?
Gilead sits in large, chronic disease markets where patients need treatment for years, sometimes for life.
- HIV is a lifelong condition requiring ongoing therapy
- Cancer treatments are a growing global market
- Aging populations increase demand for specialty drugs
Investor takeaway
Durable demand base
Chronic diseases create recurring revenue streams that can last decades if new drugs keep coming.
Based on company financial statements.
Benchmark Comparison
How has Gilead Sciences, Inc. performed against common long-term benchmarks?
Once the business case is clear, compare the stock against broad market and alternative long-term baselines.
$2,227
+122.7% total return
$1,753
+75.3% total return
$2,975
+197.5% total return
$1,393
+39.3% total return
| Asset | Total Return | Dollar Value |
|---|---|---|
| GILD | +122.7% | $2,227 |
| S&P 500 | +75.3% | $1,753 |
| Gold | +197.5% | $2,975 |
| Bitcoin | +39.3% | $1,393 |
From Mar 5, 2021 to Mar 6, 2026. Historical price data based on company financial statements and market indices. Each card uses the same starting amount so the comparison stays apples-to-apples.
Investor Fit
How a first-time investor could frame Gilead Sciences, Inc.
Before going deeper, decide what kind of business this is, what it tends to suit, and what deserves monitoring over time.
This Can Fit If You Want
- A profitable healthcare company with a 28.9 percent net margin
- Strong cash generation with a 32.1 percent free cash flow margin
- Exposure to long-term demand in HIV and oncology
Be Careful If You Expect
- Fast revenue growth, revenue has grown about 1.9 percent per year over five years
- A simple, diversified revenue base without patent risk
- No exposure to political debates on drug pricing
What To Watch Over Time
- Whether new drugs offset patent expirations
- Research spending effectiveness and approval success rates
- Capital allocation between buybacks, acquisitions, and internal research
Key Metrics
Which metrics matter most for Gilead Sciences, Inc. right now?
Three durable business metrics that matter more than day-to-day price moves.
1.9% average annual growth (5 years)
8.4% average annual growth (5 years)
86.7% gross margin
| Metric | Value | Context |
|---|---|---|
| Revenue Growth | 1.9% average annual growth (5 years) | Shows whether the business has been expanding fast enough to create more long-term value. |
| EPS Growth | 8.4% average annual growth (5 years) | Shows whether earnings per share are compounding for owners over time. |
| Margin Quality | 86.7% gross margin | Shows how much room the business has to fund growth, absorb shocks, and stay profitable. |
Based on company financial statements.
Fundamentals
What do Gilead Sciences, Inc.'s fundamentals say right now?
Core financial markers that explain how the business is performing beneath the stock price.
14.1% ROIC
86.7% gross margin
32.1% FCF margin
Stable to shrinking
| Metric | Value | Interpretation |
|---|---|---|
| Capital Efficiency | 14.1% ROIC | The business is currently showing fair capital efficiency. |
| Profitability | 86.7% gross margin | Healthy gross margins give the company room to invest, price competitively, and absorb shocks. |
| Cash Generation | 32.1% FCF margin | Free cash flow margin shows how much real cash the business keeps after funding operations and investment. |
| Ownership Trend | Stable to shrinking | The company is not currently diluting owners and may be buying back shares instead. |
Based on company financial statements.
Included In Funds
Which ETFs and funds currently hold Gilead Sciences, Inc.?
Gilead Sciences, Inc. currently appears in these ETF and fund proxies.
QQQ
Invesco QQQ Trust, Series 1
SPY
SPDR S&P 500 ETF Trust
IWB
iShares Russell 1000 ETF
Questions & Answers
What questions come up most often about Gilead Sciences, Inc.?
Company-specific questions readers often ask about Gilead Sciences, Inc..
Each entry answers a direct question about the business, the long-term thesis, or the risks that matter over time.
Gilead develops and sells patented prescription medicines, mainly for HIV, cancer, and serious viral diseases.
Decision Framing
Secondary context after the long-term thesis
Shorter-horizon context and comparison tools, after the core long-term read.
Shorter-horizon price moves, two-sided debate, and comparison tools live here so the page stays anchored on business quality, durability, and BinaPrint fit first.
Investment Thesis
Bull vs Bear
Two-sided framing before any decision.
Current argument weight is balanced.
Bull case
What can work
HIV remains a lifelong condition, creating recurring revenue streams as patients stay on therapy for decades, providing durable demand.
An 86.7 percent gross margin and 40.1 percent operating margin provide enormous internal funding for research and acquisitions.
Scale in clinical trials and global regulatory expertise makes it harder for smaller biotech firms to compete alone.
Strong cash conversion, with free cash flow exceeding net income, allows consistent reinvestment without stressing the balance sheet.
Bear case
What can break
Patent expirations can cause sharp revenue declines if new drugs fail to replace aging blockbusters.
Drug pricing reforms or government negotiation could compress margins that currently sit near 29 percent at the net level.
Scientific failure is always possible, late-stage trial setbacks could erase years of research investment.
Breakthrough technologies from competitors, such as curative therapies, could disrupt chronic treatment models in HIV or oncology.
Risk Radar
Key Risks
Where downside pressure can build.
Patent concentration, a small number of flagship drugs likely account for a large share of profit, and loss of exclusivity could materially cut revenue.
Regulatory and pricing risk, high margins of 40.1 percent operating profit could be pressured by policy changes.
Pipeline risk, heavy research spending may not yield sufficient new approvals to sustain even 2 percent annual revenue growth.
Pressure points
Concentration risk
Gilead has historically relied heavily on a concentrated set of HIV therapies for a significant portion of revenue. If one or two key drugs lose exclusivity or face superior competition, the financial impact could be meaningful given the company’s modest overall revenue growth rate.
Sizing matters
Risks should be read as scenario inputs, not certainties. Position size and time horizon determine how much of this downside profile is acceptable.
Market Snapshot
Tactical context after the core long-term read.
- Price
- $143.93
- Daily move
- -0.83%
Peer Set
A compact peer list for side-by-side context.
Next Actions
Explore planning scenarios or keep browsing similar companies.